Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Total Liabilities
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has total liabilities worth $18.14 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See DMII net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Drugs Made In America Acquisition II Corp. Ordinary Shares - Total Liabilities Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Drugs Made In America Acquisition II Cor's balance sheet.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥7.37 Billion |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd A
SHG:600819
|
China | CN¥3.70 Billion |
|
Lindian Resources Ltd
AU:LIN
|
Australia | AU$18.19 Million |
|
Qingdao Weflo Valve Co Ltd
SHE:002871
|
China | CN¥274.40 Million |
|
Huali Industries
SHG:603038
|
China | CN¥1.23 Billion |
|
Skjern Bank A/S
CO:SKJE
|
Denmark | Dkr13.79 Billion |
|
Nova Technology
TWO:6613
|
Taiwan | NT$6.96 Billion |
|
Stratasys Ltd
NASDAQ:SSYS
|
USA | $230.86 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Drugs Made In America Acquisition II Corp. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Drugs Made In America Acquisition II Cor (DMII) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Drugs Made In America Acquisition II Corp. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual total liabilities of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.80 Million | +6886.68% |
| 2024-12-31 | $254.78K | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more